Influenza vector vaccine - Pharmenterprises
Alternative Names: UniFluVec; VTH-201Latest Information Update: 28 Sep 2022
At a glance
- Originator Pharmenterprises
- Class Attenuated vaccines; Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Russia (Intranasal, Aerosol)
- 09 Dec 2020 Pharmenterprises terminates its license agreement with Vacthera prior to December 2020 (Communication, December 2020)
- 31 Mar 2020 Pharmenterprises completes the phase I trial in Influenza virus infection (Prevention) in Russia (Intranasal) (NCT04650971)